This article was originally published in The Gray Sheet
One year angiographic substudy results show up to a 60% decrease in mortality for patients randomized to stent placement plus abciximab over patients randomized to stent plus placebo or angioplasty with abciximab, reports Michael Lincoff, MD, Cleveland Clinic, at a Nov. 9 AHA press conference. Commenting on the 900-patient substudy, Lincoff noted: "Mortality is generally something we don't see a significant difference in trials this size because unfortunately death occurs frequently in this population of patients." The substudy hoped to cover as broad a clinical population as possible, he noted. Lincoff reported statistically significant mortality results of 2.4% for the placebo+stent group, 2.1% for the angioplasty+abciximab group, and 1.0% in stent +abciximab group
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.